Patent ID: 8771703

Claim:
A recombinant hemagglutinin (rHA), comprising: a) a hemagglutinin domain selected from the group consisting of hemagglutinin subtypes H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16; b) an oligomerization domain selected from the group consisting of a GCN4-pII peptide, a proline rich domain (PRD) of maize γ-zein, and a bacteriophage T4 fibritin; wherein amino acid residues are added to the C-terminal end of the oligomerization domain such that the oligomerization domain from GCN4-pII or bacteriophage T4 fibritin does not terminate in an α-helix and the oligomerization domain from the PRD of maize γ-zein does not terminate in an amphipathic polyproline II helix; c) a signal peptide; and d) an endoplasmic reticulum (ER) retention signal; wherein the rHA is produced as a chimeric soluble homotrimer.